Byhealth Co., Ltd Stocks

CN¥ 10.56Last Updated 29.04.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 2.62B

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 10.56
Key Takeaways

Risk factor

Strong trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

By-health Co., Ltd. produces and sells dietary supplements worldwide. The company offers proteins and vitamins/minerals; and various products for skeleton and joints, heart and cerebral vessels, beauty maintenance, immunity boosting, weight management, vigor enhancement, eye nutrition, sleep improvement, blood glucose management, memory improvement, reproductive health, childhood nutrition, and pregnant women nutrition, as well as for liver, intestines, and stomach. It provides its products for children, men, women, and elderly people under the By-health and GymMax brand names through distributors, retail terminals, and online channels. The company was formerly known as Guangdong By-Health Biotechnology Co., Ltd. and changed its name to By-health Co., Ltd. in April 2012. By-health Co., Ltd. was founded in 1995 and is headquartered in Guangzhou, China.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of 300146.SZ is 13 and suggests 21% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks